These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15778051)

  • 1. Cremophor EL releases cyclosporin A adsorbed on blood cells and blood vessels, and increases apparent plasma concentration of cyclosporin A.
    Jin M; Shimada T; Yokogawa K; Nomura M; Mizuhara Y; Furukawa H; Ishizaki J; Miyamoto K
    Int J Pharm; 2005 Apr; 293(1-2):137-44. PubMed ID: 15778051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A; Verweij J; van der Burg ME; Loos WJ; Brouwer E; Viganò L; Locatelli A; de Vos AI; Nooter K; Stoter G; Gianni L
    Clin Cancer Res; 1998 Aug; 4(8):1937-42. PubMed ID: 9717822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A; van Zuylen L; Brouwer E; Loos WJ; de Bruijn P; Gelderblom H; Pillay M; Nooter K; Stoter G; Verweij J
    Cancer Res; 1999 Apr; 59(7):1454-7. PubMed ID: 10197613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K; Jin M; Furui N; Yamazaki M; Yoshihara H; Nomura M; Furukawa H; Ishizaki J; Fushida S; Miwa K; Miyamoto K
    J Pharm Pharmacol; 2004 May; 56(5):629-34. PubMed ID: 15142340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
    Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H; Verweij J; van Zomeren DM; Buijs D; Ouwens L; Nooter K; Stoter G; Sparreboom A
    Clin Cancer Res; 2002 Apr; 8(4):1237-41. PubMed ID: 11948138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues.
    Tanaka C; Kawai R; Rowland M
    Drug Metab Dispos; 2000 May; 28(5):582-9. PubMed ID: 10772639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary delivery of intratracheally instilled and aerosolized cyclosporine A to young and adult rats.
    Taljanski W; Pierzynowski SG; Lundin PD; Westrom BR; Eirefelt S; Podlesny J; Dahlback M; Siwinska-Golebiowska H; Karlsson BW
    Drug Metab Dispos; 1997 Aug; 25(8):917-20. PubMed ID: 9280398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-kappaB activation or iNOS expression.
    Gutiérrez MB; Miguel BS; Villares C; Gallego JG; Tuñón MJ
    Toxicology; 2006 May; 222(1-2):125-31. PubMed ID: 16533553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
    Brouwer E; Verweij J; Hauns B; Loos WJ; Nooter K; Mross K; Stoter G; Sparreboom A
    Anal Biochem; 1998 Aug; 261(2):198-202. PubMed ID: 9716422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L; Gianni L; Verweij J; Mross K; Brouwer E; Loos WJ; Sparreboom A
    Anticancer Drugs; 2000 Jun; 11(5):331-7. PubMed ID: 10912949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomal formulations of cyclosporin A: influence of lipid type and dose on pharmacokinetics.
    Fahr A; Holz M; Fricker G
    Pharm Res; 1995 Aug; 12(8):1189-98. PubMed ID: 7494833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone.
    Yokogawa K; Shimada T; Higashi Y; Itoh Y; Masue T; Ishizaki J; Asahi M; Miyamoto K
    Biochem Pharmacol; 2002 Feb; 63(4):777-83. PubMed ID: 11992648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of atropine on gastrointestinal motility and the bioavailability of cyclosporine A in rats.
    Quijano RF; Ohnishi N; Umeda K; Komada F; Iwakawa S; Okumura K
    Drug Metab Dispos; 1993; 21(1):141-3. PubMed ID: 8095208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of decrease of oral bioavailability of cyclosporin A during immunotherapy upon coadministration of amphotericin B.
    Ishizaki J; Ito S; Jin M; Shimada T; Ishigaki T; Harasawa Y; Yokogawa K; Takami A; Nakao S; Miyamoto K
    Biopharm Drug Dispos; 2008 May; 29(4):195-203. PubMed ID: 18240156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of gonadectomy on cyclosporine pharmacokinetics in male and female rats.
    Molpeceres J; Chacón M; Aberturas MR; Guzmán M; Díez ML; Rodriguez-Puyol M
    Pharmazie; 2001 Jan; 56(1):78-82. PubMed ID: 11210676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states.
    Shibata N; Shimakawa H; Minouchi T; Yamaji A
    Biol Pharm Bull; 1993 Nov; 16(11):1130-5. PubMed ID: 8312870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo studies of cyclosporin A-loaded microspheres based on copolymers of lactide and epsilon-caprolactone: comparison with conventional PLGA microspheres.
    Li Y; Zhu KJ; Zhang JX; Jiang HL; Liu JH; Hao YL; Yasuda H; Ichimaru A; Yamamoto K
    Int J Pharm; 2005 May; 295(1-2):67-76. PubMed ID: 15847992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of appropriate blood level in continuous intravenous infusion from trough concentrations after oral administration based on area under trough level in tacrolimus and cyclosporine therapy.
    Nakamura Y; Takeuchi H; Okuyama K; Akashi T; Jojima Y; Konno O; Akashi I; Hama K; Iwahori T; Ashizawa T; Hirano T; Oka K; Matsuno N; Nagao T
    Transplant Proc; 2005 May; 37(4):1725-7. PubMed ID: 15919445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.